Besides, subcutaneous administration of the nanoformulation leads to its migration to the draining lymph nodes, where it subsequently activates DCs as well as CD8+ T cells (cytotoxic T cells), resulting in increased anticancer response in bladder, melanoma and renal carcinoma models, thereby proving the role of PLGA NPs as potent immunostimulatory adjuvants for cancer immunotherapy. Here, CD8A is linked to cancer.